Does HBOT Actually Lengthen Telomeres? What the Research Says and What It Does Not
The Study Everyone Cites and Almost Nobody Reads
If you have spent any time researching hyperbaric oxygen and aging, you have encountered a version of this claim: a study out of Tel Aviv showed that HBOT lengthened telomeres and cleared senescent cells in older adults, reversing markers of biological aging.
That claim is broadly accurate. The study exists, it was published in a peer reviewed journal, and the numbers are striking.
It is also routinely described in ways the paper does not support. The most common error, which appears on wellness sites and in HBOT marketing across the country, is that participants were compared against a control group who received no intervention. They were not. Understanding why that matters, and what the study can still legitimately tell you, is the difference between reading research and repeating headlines.
We have written separately about what a realistic approach to aging looks like day to day, and that piece is the better starting point if you want the philosophy. This one is narrower. It is about the evidence, the mechanism underneath it, and how much weight each piece can carry.
What Cellular Aging Actually Refers To
Two of the better characterized hallmarks of aging are worth defining precisely, because the research turns on them.
Telomeres are repetitive DNA sequences capping the ends of chromosomes. They protect coding DNA during replication, and they shorten with each cell division because DNA polymerase cannot fully copy the end of a linear strand. When telomeres reach a critical length, the cell stops dividing.
Senescence is what happens next. The cell does not die. It enters a permanent non dividing state while remaining metabolically active, and it begins secreting a mix of inflammatory cytokines, chemokines, and proteases known as the senescence associated secretory phenotype, or SASP. That secretion is the problem. Senescent cells actively degrade the tissue environment around them and can push neighboring cells toward senescence as well. Their accumulation is a major contributor to the chronic low grade inflammation that characterizes aging, and clearing them is one of the most actively pursued strategies in longevity biology.
So when a study reports both longer telomeres and fewer senescent cells, it is reporting movement on two hallmarks that are mechanistically linked.
What the 2020 Trial Actually Found
Hachmo and colleagues at the Sagol Center in Israel enrolled healthy adults aged 64 and over with no cognitive or physical decline, and ran them through 60 daily hyperbaric sessions across roughly three months. Blood was drawn at baseline, at the 30th session, at the 60th, and again one to two weeks afterward.
<cite index="7-1">Telomere length increased by roughly 38% in B cells, about 29% in T helper cells, and around 22% in natural killer cells. Senescent T helper cells dropped by about 37%.</cite> <cite index="11-1">Thirty participants completed the protocol, with telomere analysis available for 25 and senescence analysis for 20.</cite>
Those are large effects, and telomere lengthening in older adults through a non pharmacological intervention had not been clearly shown before.
Now the design. The paper is titled a prospective trial, not a randomized controlled trial. Participants served as their own controls, with each measurement compared against that person's own baseline. There was no separate arm receiving nothing. <cite index="7-1">The trials had no placebo control groups, and the samples were small.</cite>
That does not make the findings worthless. It makes them hypothesis generating rather than confirmatory. Without a control arm you cannot separate the effect of the intervention from regression to the mean, from seasonal variation, from the assay drift that plagues telomere measurement, or from whatever else changes in a person's life across three months of showing up somewhere daily. Twenty five people is a small number for a measurement with known variability.
The honest summary is this: a well conducted single arm trial found large changes in two aging markers, and the finding warrants a randomized controlled replication that has not yet been published. Anyone telling you it proves biological age reversal is going further than the authors did.
The Mechanism, Which Is Genuinely Counterintuitive
The interesting part is why elevated oxygen would trigger a regenerative response at all. Intuitively you would expect the opposite, since the regenerative programs in question are the ones the body runs during oxygen shortage.
Hadanny and Efrati named this the hyperoxic-hypoxic paradox in a 2020 review in Biomolecules, and the explanation turns on how cells sense oxygen. <cite index="14-1">Fluctuations in free oxygen concentration, rather than the absolute level, can be read at the cellular level as a lack of oxygen.</cite>
The mechanics run through a transcription factor called hypoxia-inducible factor 1 alpha. Under normal oxygen conditions, HIF-1 alpha is continuously produced and continuously destroyed: enzymes called prolyl hydroxylases tag it for degradation, and they require oxygen to work. When oxygen drops, tagging slows, HIF-1 alpha accumulates, enters the nucleus, and switches on genes governing angiogenesis, stem cell mobilization, and metabolic adaptation.
A hyperbaric session floods tissue with oxygen and then ends. The subsequent return to normal is read by the cell as a relative decline, and the hypoxic response machinery engages even though absolute oxygen never fell below baseline. The signal is the swing, not the level.
This is also why <cite index="14-1">hypoxia is described as one of the most powerful inducers of gene expression, metabolic change, and regenerative processes including angiogenesis and stem cell proliferation, migration, and differentiation.</cite> Repeated intermittent exposure is being used to borrow that program without the cost of actual oxygen deprivation, which is closely related to the cellular energy story we cover separately.
Hyperbaric Oxygen Therapy is a systemic modality that influences the human body on cellular and physiological level, and this is the clearest illustration of why that framing is accurate rather than promotional. The pathway being engaged is a global transcriptional program, not a local effect on one tissue.
The Stem Cell Finding, Which Has Better Mechanistic Support
The most methodologically satisfying study in this area is older and gets cited less than the telomere work, which is unfortunate because its causal reasoning is stronger.
Thom and colleagues at the University of Pennsylvania published in the American Journal of Physiology in 2006. <cite index="21-1">Circulating CD34+ cells doubled after a single two hour exposure at 2.0 ATA, and increased eightfold over a course of 20 treatments, while overall white cell count did not significantly change.</cite> CD34+ cells are bone marrow derived progenitors that contribute to vascular and tissue repair.
Two details make this study more than a correlation. <cite index="24-1">Mobilization was attributable to hyperoxia rather than pressure alone, because no increase appeared in paramedics who accompanied patients inside the chamber breathing air at the same 2.0 ATA.</cite> And <cite index="23-1">mobilization did not occur in mice lacking the gene for endothelial nitric oxide synthase, and pre-treating normal mice with a nitric oxide synthase inhibitor prevented it.</cite>
That is a proper mechanistic chain: an internal control ruling out pressure as the driver, and a genetic knockout identifying the required pathway. It tells you what is happening and why.
What it does not tell you is whether more circulating progenitor cells produces any outcome a person would notice. Mobilization is a measurable intermediate, not a result. That gap is real and worth holding onto.
Skin, Where the Effects Are Visible
A 2021 follow up from the same Israeli group took skin biopsies, which is useful because skin is one of the few tissues where structural aging can be examined directly.
The design here was better than the telomere study. <cite index="28-1">Participants went through a three month control period with no intervention before beginning three months of daily HBOT, with biopsies at baseline, after the control period, and following the final session.</cite> Each participant effectively provided their own untreated comparison window.
<cite index="31-1">Following HBOT there was a significant increase in collagen density, elastic fiber length, and the number of blood vessels, along with a significant decrease in fiber fragmentation and in tissue senescent cells. No changes were seen in elastic fiber density or thickness.</cite>
<cite index="28-1">Thirteen male participants out of a cohort of 70 consented to repeat biopsies.</cite> That is a very small sample, and the negative findings are reported alongside the positive ones, which is a mark in the paper's favor. The angiogenesis result also connects cleanly back to the HIF-1 alpha mechanism above, which is the kind of coherence that makes a body of evidence more persuasive than any single study within it.
The One Randomized Trial
For contrast, there is a properly controlled study in this population, and it is worth knowing about precisely because it is the exception.
<cite index="41-1">Sixty three healthy adults over 64 were randomized to either HBOT or a control arm for three months, with cerebral blood flow measured by perfusion MRI. There was a significant group-by-time interaction in global cognitive function, with the largest improvements in attention and information processing speed, and voxel-based analysis showed increased cerebral blood flow in the HBOT group relative to control.</cite>
Randomized, controlled, with an objective imaging endpoint alongside the cognitive testing. This is the strongest single piece of evidence in the healthy aging literature on HBOT, and notably it is about cognition and perfusion rather than telomeres. If you want to know where the evidence is firmest, it is here.
That said, the control arm received no intervention rather than a sham, so expectancy effects are not excluded. Worth knowing about, and relevant to how HBOT relates to brain fog and cognitive function more broadly.
What This Adds Up To
Reading the evidence as a set rather than as isolated headlines, the picture is coherent but incomplete.
The mechanism is well described and biologically plausible, with the HIF-1 alpha pathway providing a specific explanation for why intermittent hyperoxia would trigger regenerative signaling. The stem cell mobilization work has genuine causal support from knockout models. The cognitive trial is randomized and controlled. The telomere and skin findings are striking but come from small single arm designs that need replication.
What nobody has shown is that any of this translates into living longer or living better over years and decades. The trials measure biomarkers and short term function. The outcomes that would actually matter, meaning years of independent function or reduced disease incidence, would take a decade to measure and nobody has run that study.
There is also a note on where this research comes from. A large share of the aging work originates from one center in Israel. Concentration of findings in a single group is not evidence of a problem, but independent replication is what turns a promising line of research into an established one, and that has not yet happened at scale.
The Money Question
A 60 session protocol of the kind used in these trials is a serious commitment of both time and money, and it is worth stating plainly that the studies above used exactly that: daily sessions across three months.
The reasonable way to think about it is by comparison. The longevity market in New York will sell you supplement stacks running several hundred dollars a month indefinitely, with evidence bases considerably thinner than what is described here, and with no defined endpoint. Against that, a bounded protocol with published biomarker data and a named mechanism is a more legible proposition, even accounting for the design limitations.
That is not an argument that you should do it. It is an argument for comparing like with like. You can review what HBOT costs in New York and weigh it against everything else competing for the same budget.
References
Hachmo Y, Hadanny A, Abu Hamed R, et al. Hyperbaric oxygen therapy increases telomere length and decreases immunosenescence in isolated blood cells: a prospective trial. Aging (Albany NY). 2020;12(22):22445-22456. doi:10.18632/aging.202188
Hachmo Y, Hadanny A, Mendelovic S, et al. The effect of hyperbaric oxygen therapy on the pathophysiology of skin aging: a prospective clinical trial. Aging (Albany NY). 2021;13(24):24500-24510. doi:10.18632/aging.203701
Hadanny A, Daniel-Kotovsky M, Suzin G, et al. Cognitive enhancement of healthy older adults using hyperbaric oxygen: a randomized controlled trial. Aging (Albany NY). 2020;12(13):13740-13761. doi:10.18632/aging.103571
Hadanny A, Efrati S. The hyperoxic-hypoxic paradox. Biomolecules. 2020;10(6):958. doi:10.3390/biom10060958
Thom SR, Bhopale VM, Velazquez OC, Goldstein LJ, Thom LH, Buerk DG. Stem cell mobilization by hyperbaric oxygen. Am J Physiol Heart Circ Physiol. 2006;290(4):H1378-H1386. doi:10.1152/ajpheart.00888.2005
Frequently Asked Questions
-
No, and this is the most common misstatement about it. The 2020 telomere trial was a single arm prospective study in which participants were compared against their own baseline measurements. The 2021 skin study included a three month no intervention period before treatment began, which is stronger. The separate cognitive trial from the same group was properly randomized with a control arm.
-
The published data show movement in specific biomarkers of cellular aging under specific protocols. Biomarkers are not the same as biological age, and no study has yet demonstrated effects on how long or how well people live. The honest description is promising early evidence, not demonstrated reversal.
-
Sixty daily sessions across roughly three months, at 2.0 ATA. That is a substantial protocol, and results from it should not be assumed to apply to occasional or infrequent use.
-
Cells respond to change in oxygen availability, not only to absolute levels. When a session ends and oxygen returns to normal, the relative drop stabilizes HIF-1 alpha, which activates the same genetic programs that genuine oxygen shortage would. This is the hyperoxic-hypoxic paradox.
-
It has better causal support than most of this literature. The effect disappeared in mice lacking endothelial nitric oxide synthase and in people breathing air at the same pressure, which identifies both the required pathway and rules out pressure alone. What remains unknown is whether mobilized progenitor cells produce outcomes a person would notice.
-
No. Nothing in this research suggests otherwise, and the effect sizes attached to sleep, resistance training, and nutrition across large long term studies are considerably better established than anything described here.
-
That is a conversation rather than a purchase, and it depends on your health history and what you are actually trying to address. You can see how we approach it or come talk it through with us.
What the Evidence Supports Saying
Research on hyperbaric oxygen and cellular aging is real, published in peer reviewed journals, and mechanistically coherent in a way that most of the longevity market is not. It is also early, concentrated in a small number of research groups, and built substantially on trials without control arms.
Both of those things are true simultaneously, and holding them together is the entire skill. The version of this you will encounter elsewhere usually drops one half or the other: either the research is dismissed outright, or the caveats are quietly removed and the effect sizes are presented as settled fact.
We would rather you know exactly what the studies did and decide from there. If you want to talk about whether any of it applies to you, come in and ask us hard questions.
